[Federal Register Volume 61, Number 217 (Thursday, November 7, 1996)] [Notices] [Pages 57687-57688] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 96-28682] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES [Docket No. 94P-0429] Additional Data Regarding the Composition of Conjugated Estrogens; Availability; Request for Comments AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing that additional materials have been submitted to Docket No. 94P-0429, the docket established for a citizen petition filed on November 30, 1994, on behalf of Wyeth-Ayerst Laboratories, Division of American Home Products Corp. These materials include amendments to the petition and data supporting the petition submitted by Wyeth-Ayerst as well as data submitted to the docket by FDA and other interested persons. Among the documents submitted to the docket by FDA is a document entitled ``Preliminary Analysis of Scientific Data on the Composition of Conjugated Estrogens.'' The agency is requesting comments on this document as well as on the citizen petition, amendments to the petition, and other materials in the docket. DATES: Written comments by December 9, 1996. ADDRESSES: Submit written requests for single copies of the document entitled ``Preliminary Analysis of Scientific Data on the Composition of Conjugated Estrogens'' to the Drug Information Branch, Division of Communications Management (HFD-210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send two self-addressed adhesive labels to assist that office in processing your requests. Submit written comments on the materials submitted to the docket to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. Two copies of any comments are to be submitted, except that individuals may submit one. Requests and comments should be identified with the docket number found in brackets in the heading of this document. Materials related to the Wyeth-Ayerst citizen petition on conjugated estrogens are available for public examination in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. FOR FURTHER INFORMATION CONTACT: Diane Sullivan-Ford, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 7500 Standish [[Page 57688]] Pl., Rockville, MD 20855, 301-594-2041. SUPPLEMENTARY INFORMATION: On November 30, 1994, a citizen petition was filed on behalf of Wyeth-Ayerst Laboratories, Division of American Home Products Corp. The petition was amended on December 2, 1994; September 26, 1995; November 6, 1995; March 8, 1996; March 15, 1996; and June 27, 1996. The citizen petition requests, among other things, that FDA: (1) Determine that sodium delta 8,9-dehydroestrone sulfate (delta 8,9-DHES) is a concomitant component in conjugated estrogens tablets; (2) officially recommend that the United States Pharmacopeial Convention amend the United States Pharmacopeia (USP) monograph for conjugated estrogens and conjugated estrogens tablets to include delta 8,9-DHES as a concomitant component comprising at least 2 percent but not more than 6 percent of the estrogens in these products; and (3) not accept for filing or receive or approve any new drug application (NDA) or abbreviated new drug application (ANDA) for a conjugated estrogens product in which delta 8,9-DHES does not comprise at least 2 percent but not more than 6 percent of its estrogens. Amendments to the petition raised issues concerning the contribution of delta 8,9-DHES to the clinical effect of Premarin. FDA is inviting comments on this as well as any other issues raised in the citizen petition and amendments as well as on issues raised in comments received on the petition. In addition, FDA has placed in the docket a document entitled ``Preliminary Analysis of Scientific Data on the Composition of Conjugated Estrogens'' which addresses some of the issues and data submitted in the citizen petition and amendments. This document presents the agency's preliminary analysis of certain currently available data relating to the contribution of estrone sulfate, equilin sulfate, and delta 8,9-DHES to the clinical effects of Premarin, including effects on bone mineral density. The document does not respond to the citizen petition nor does it announce any action with regard to any pending application or accepting any future application for a conjugated estrogens drug product or indication for use of such a product. Interested persons may, on or before December 9, 1996, submit to the Dockets Management Branch (address above) written comments regarding materials submitted to the docket. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Materials related to the Wyeth-Ayerst citizen petition on conjugated estrogens and received comments may be seen in the office above between a.m. and 4 p.m., Monday through Friday. Comments submitted after December 9, 1996 may not be considered by the agency. Dated: October 31, 1996. William B. Schultz, Deputy Commissioner for Policy. [FR Doc. 96-28682 Filed 11-04-96; 3:24 pm] BILLING CODE 4160-01-F